Literature DB >> 2199348

Bile duct antibodies crossreacting with blood group antigens in primary sclerosing cholangitis.

G P Jeffrey1, N R Swanson, L J Yarred, W D Reed.   

Abstract

Indirect immunoperoxidase histochemistry was used to localise and determine the disease, species, and tissue specificity of bile duct antibodies in primary sclerosing cholangitis. Serum was collected from: 29 patients with primary sclerosing cholangitis, 18 patients with ulcerative colitis alone, 19 patients with extrahepatic biliary obstruction of other causes, and 42 healthy control subjects. Bile duct antibodies reacted with an antigen localised to the small and large intrahepatic bile ducts. When blood group A human liver was used they were detected in 34% of patients with primary sclerosing cholangitis. They were not detected when blood group O human liver was used. Bile duct antibodies that reacted with obstructed and normal rabbit liver were detected in 34% and 17% respectively of patients with primary sclerosing cholangitis but were also present in similar proportions of control subjects. Colon antibodies that reacted with human and rabbit colon were found in 52% and 24% respectively of patients with primary sclerosing cholangitis. Absorption studies using blood group substances A and B abolished the reactivity of bile duct antibodies with human and rabbit liver and that of colon antibodies' with rabbit colon. Colon antibodies that reacted with human colon were not absorbed. Absorption studies using isolated peripheral white blood cells did not affect reactivity of bile duct or colon antibodies. We conclude that bile duct antibodies are disease, species, and tissue non-specific and react with blood group A/B antigens present in human and rabbit bile ducts and rabbit colon. This suggests that they do not play a role in the pathogenesis of primary sclerosing cholangitis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2199348      PMCID: PMC1378500          DOI: 10.1136/gut.31.6.698

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  13 in total

1.  Immunocytochemical studies in ulcerative colitis and regional ileitis.

Authors:  D KOFFLER; S MINKOWITZ; W ROTHMAN; J GARLOCK
Journal:  Am J Pathol       Date:  1962-12       Impact factor: 4.307

2.  Immunocytochemical reaction of serum of patients with hepatic diseases with hepatic structures.

Authors:  F PARONETTO; F SCHAFFNER; H POPPER
Journal:  Proc Soc Exp Biol Med       Date:  1961-01

3.  Primary sclerosing cholangitis: clinical and immunopathological review of 21 cases.

Authors:  G P Jeffrey; W D Reed; B H Laurence; K B Shilkin
Journal:  J Gastroenterol Hepatol       Date:  1990 Mar-Apr       Impact factor: 4.029

4.  Blood group antigens in the intrahepatic biliary tree. I. Distribution in the normal liver.

Authors:  Y Okada; K Jinno; S Moriwaki; T Shimoe; T Tsuji; M Murakami; J Thurin; H Koprowski
Journal:  J Hepatol       Date:  1988-02       Impact factor: 25.083

5.  Auto-immune reactions in ulcerative colitis.

Authors:  R Wright; S C Truelove
Journal:  Gut       Date:  1966-02       Impact factor: 23.059

6.  Intrahepatic cholangiectases and large-duct obliteration in primary sclerosing cholangitis.

Authors:  J Ludwig; R L MacCarty; N F LaRusso; R A Krom; R H Wiesner
Journal:  Hepatology       Date:  1986 Jul-Aug       Impact factor: 17.425

7.  Current concepts. Primary sclerosing cholangitis.

Authors:  N F LaRusso; R H Wiesner; J Ludwig; R L MacCarty
Journal:  N Engl J Med       Date:  1984-04-05       Impact factor: 91.245

8.  Association of primary sclerosing cholangitis with HLA-B8.

Authors:  R W Chapman; Z Varghese; R Gaul; G Patel; N Kokinon; S Sherlock
Journal:  Gut       Date:  1983-01       Impact factor: 23.059

9.  Serum autoantibodies, ulcerative colitis and primary sclerosing cholangitis.

Authors:  R W Chapman; M Cottone; W S Selby; H A Shepherd; S Sherlock; D P Jewell
Journal:  Gut       Date:  1986-01       Impact factor: 23.059

10.  The in vivo metabolism of C3 in hepatobiliary disease associated with ulcerative colitis.

Authors:  L Brinch; P Teisberg; E Schrumpf; I Akesson
Journal:  Scand J Gastroenterol       Date:  1982-06       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.